JP2013525786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525786A5 JP2013525786A5 JP2013506214A JP2013506214A JP2013525786A5 JP 2013525786 A5 JP2013525786 A5 JP 2013525786A5 JP 2013506214 A JP2013506214 A JP 2013506214A JP 2013506214 A JP2013506214 A JP 2013506214A JP 2013525786 A5 JP2013525786 A5 JP 2013525786A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- molecule
- sample
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000004481 post-translational protein modification Effects 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 230000021736 acetylation Effects 0.000 claims description 4
- 238000006640 acetylation reaction Methods 0.000 claims description 4
- 230000009435 amidation Effects 0.000 claims description 4
- 238000007112 amidation reaction Methods 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 230000009635 nitrosylation Effects 0.000 claims description 4
- 230000034512 ubiquitination Effects 0.000 claims description 4
- 238000010798 ubiquitination Methods 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 3
- 238000006366 phosphorylation reaction Methods 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 201000001441 melanoma Diseases 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 8
- 235000018102 proteins Nutrition 0.000 claims 8
- 238000012360 testing method Methods 0.000 claims 8
- 230000011664 signaling Effects 0.000 claims 7
- 230000037361 pathway Effects 0.000 claims 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 5
- 102000007982 Phosphoproteins Human genes 0.000 claims 5
- 108010089430 Phosphoproteins Proteins 0.000 claims 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 5
- 239000003102 growth factor Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102000047916 Epidermal growth factor receptor ligand Human genes 0.000 claims 4
- 108700037877 Epidermal growth factor receptor ligand Proteins 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000002151 Pleural effusion Diseases 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 206010003445 Ascites Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 3
- 206010030113 Oedema Diseases 0.000 claims 3
- 208000005228 Pericardial Effusion Diseases 0.000 claims 3
- 210000004381 amniotic fluid Anatomy 0.000 claims 3
- 230000005775 apoptotic pathway Effects 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 230000004640 cellular pathway Effects 0.000 claims 3
- 230000005754 cellular signaling Effects 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 238000000684 flow cytometry Methods 0.000 claims 3
- 238000004949 mass spectrometry Methods 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 230000037353 metabolic pathway Effects 0.000 claims 3
- 230000006712 oncogenic signaling pathway Effects 0.000 claims 3
- 210000004912 pericardial fluid Anatomy 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 210000003296 saliva Anatomy 0.000 claims 3
- 210000000582 semen Anatomy 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 210000004243 sweat Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 210000001138 tear Anatomy 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000009036 biliary tract cancer Diseases 0.000 claims 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 230000006482 proangiogenic pathway Effects 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 230000037364 MAPK/ERK pathway Effects 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000027067 Paget disease of bone Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 241000589970 Spirochaetales Species 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 241000159243 Toxicodendron radicans Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 230000006481 angiogenic pathway Effects 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 206010007625 cardiogenic shock Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000017983 photosensitivity disease Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 238000004902 predicting drug resistance Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 201000004335 respiratory allergy Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 102000009076 src-Family Kinases Human genes 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 208000005057 thyrotoxicosis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32571710P | 2010-04-19 | 2010-04-19 | |
| US61/325,717 | 2010-04-19 | ||
| US35649510P | 2010-06-18 | 2010-06-18 | |
| US61/356,495 | 2010-06-18 | ||
| US42117810P | 2010-12-08 | 2010-12-08 | |
| US61/421,178 | 2010-12-08 | ||
| US201161443146P | 2011-02-15 | 2011-02-15 | |
| US61/443,146 | 2011-02-15 | ||
| PCT/US2011/032935 WO2011133477A2 (en) | 2010-04-19 | 2011-04-18 | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243869A Division JP6580546B2 (ja) | 2010-04-19 | 2016-12-16 | 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525786A JP2013525786A (ja) | 2013-06-20 |
| JP2013525786A5 true JP2013525786A5 (OSRAM) | 2016-06-16 |
| JP6158078B2 JP6158078B2 (ja) | 2017-07-05 |
Family
ID=44834747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013506214A Expired - Fee Related JP6158078B2 (ja) | 2010-04-19 | 2011-04-18 | 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 |
| JP2016243869A Expired - Fee Related JP6580546B2 (ja) | 2010-04-19 | 2016-12-16 | 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243869A Expired - Fee Related JP6580546B2 (ja) | 2010-04-19 | 2016-12-16 | 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9766249B2 (OSRAM) |
| EP (1) | EP2561368B1 (OSRAM) |
| JP (2) | JP6158078B2 (OSRAM) |
| KR (1) | KR101977875B1 (OSRAM) |
| CN (2) | CN108535465A (OSRAM) |
| AU (1) | AU2011242990B2 (OSRAM) |
| CA (1) | CA2795362C (OSRAM) |
| ES (1) | ES2650674T3 (OSRAM) |
| HK (1) | HK1258688A1 (OSRAM) |
| PL (1) | PL2561368T3 (OSRAM) |
| SG (1) | SG184507A1 (OSRAM) |
| WO (1) | WO2011133477A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0913578A2 (pt) | 2008-05-14 | 2017-06-06 | Dermtech Int | diagnose de melanoma e lentigo solar por análise de ácido nucléico |
| CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| WO2014145705A2 (en) | 2013-03-15 | 2014-09-18 | Battelle Memorial Institute | Progression analytics system |
| CN104152397A (zh) * | 2013-05-13 | 2014-11-19 | 复旦大学 | 一种致敏动物的脾细胞模型及其在药物筛选中的用途 |
| GB201314485D0 (en) * | 2013-08-13 | 2013-09-25 | Electrophoretics Ltd | Materials and methods relating to pancreatic cancer |
| EP3052129A2 (en) * | 2013-09-30 | 2016-08-10 | Daiichi Sankyo Company, Limited | Protein biomarker and uses thereof |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| CN104745700A (zh) * | 2015-03-27 | 2015-07-01 | 南京医科大学 | 一种食管癌相关甲基化生物标志物及应用 |
| JP6910339B2 (ja) * | 2015-07-07 | 2021-07-28 | ジェネンテック， インコーポレイテッド | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
| WO2017136603A1 (en) * | 2016-02-02 | 2017-08-10 | Guardant Health, Inc. | Cancer evolution detection and diagnostic |
| CN105524973A (zh) * | 2016-03-15 | 2016-04-27 | 南京华奥生物医药技术有限公司 | 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法 |
| CN107091930B (zh) * | 2017-03-07 | 2020-09-15 | 杭州百凌生物科技有限公司 | 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法 |
| CN107271672B (zh) * | 2017-06-21 | 2019-01-01 | 首都医科大学附属北京友谊医院 | 外泌体p-ERK在制备结直肠癌诊断产品中的应用 |
| KR102094802B1 (ko) * | 2017-10-24 | 2020-03-31 | 고려대학교 산학협력단 | 소변 대사체 분석을 이용한 베체트병의 진단방법 |
| US20200325543A1 (en) * | 2017-11-20 | 2020-10-15 | Tolremo Therapeutics Ag | Diagnostic method |
| TWI683905B (zh) * | 2017-11-21 | 2020-02-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法 |
| US11976332B2 (en) | 2018-02-14 | 2024-05-07 | Dermtech, Inc. | Gene classifiers and uses thereof in non-melanoma skin cancers |
| AU2020247911A1 (en) | 2019-03-26 | 2021-11-11 | Dermtech, Llc | Novel gene classifiers and uses thereof in skin cancers |
| KR102199141B1 (ko) | 2019-05-03 | 2021-01-06 | 사회복지법인 삼성생명공익재단 | 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법 |
| GB201914517D0 (en) * | 2019-10-08 | 2019-11-20 | Randox Laboratories Ltd | Xbp1 isoform multiplex assay |
| JP2023537260A (ja) * | 2020-07-24 | 2023-08-31 | ジェネンテック， インコーポレイテッド | バイオマーカーを使用する骨髄穿刺液の血液希釈の決定 |
| US20240167102A1 (en) * | 2021-03-02 | 2024-05-23 | Dermtech, Inc. | Predicting therapeutic response |
| CN115267165A (zh) * | 2022-08-15 | 2022-11-01 | 海仕兰(上海)生物科技有限公司 | 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法 |
| KR20240037082A (ko) * | 2022-09-14 | 2024-03-21 | 아주대학교산학협력단 | 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법 |
| CN118130793B (zh) * | 2024-02-26 | 2025-07-29 | 赣南医科大学 | 视网膜母细胞瘤的生物标志物cdk12及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| WO2006026710A2 (en) * | 2004-08-31 | 2006-03-09 | The Johns Hopkins University | Rapid prognostic assay for malignancies treated with epidermal growth factor receptor |
| KR101381331B1 (ko) | 2005-05-09 | 2014-04-04 | 테라노스, 인코포레이티드 | 현장진료 유체 시스템 및 그 용도 |
| JP5208730B2 (ja) * | 2005-05-18 | 2013-06-12 | ノバルティス アーゲー | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
| CN101194027B (zh) | 2005-06-08 | 2012-10-24 | 日立化成研究中心公司 | 用于基于瘤细胞及受刺激的白细胞内mRNA表达谱而预测对肿瘤疾病的免疫应答的方法 |
| WO2007028005A2 (en) | 2005-09-01 | 2007-03-08 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators |
| WO2007143183A2 (en) | 2006-06-04 | 2007-12-13 | Soner Altiok | Methods for developing and assessing therapeutic agents |
| EP2899541A1 (en) * | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
| US20090098594A1 (en) * | 2007-08-21 | 2009-04-16 | Nodality, Inc. | Methods for diagnosis prognosis and methods of treatment |
| EP2210080B1 (en) | 2007-10-24 | 2015-01-28 | Biomarker Strategies, Llc | Improved methods and devices for cellular analysis |
| WO2009073513A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
-
2011
- 2011-04-18 AU AU2011242990A patent/AU2011242990B2/en not_active Ceased
- 2011-04-18 SG SG2012074746A patent/SG184507A1/en unknown
- 2011-04-18 KR KR1020127029888A patent/KR101977875B1/ko not_active Expired - Fee Related
- 2011-04-18 WO PCT/US2011/032935 patent/WO2011133477A2/en not_active Ceased
- 2011-04-18 PL PL11772505T patent/PL2561368T3/pl unknown
- 2011-04-18 JP JP2013506214A patent/JP6158078B2/ja not_active Expired - Fee Related
- 2011-04-18 US US13/089,219 patent/US9766249B2/en not_active Expired - Fee Related
- 2011-04-18 CN CN201810296066.8A patent/CN108535465A/zh active Pending
- 2011-04-18 CA CA2795362A patent/CA2795362C/en active Active
- 2011-04-18 ES ES11772505.1T patent/ES2650674T3/es active Active
- 2011-04-18 CN CN201180030332.9A patent/CN102947706B/zh not_active Expired - Fee Related
- 2011-04-18 EP EP11772505.1A patent/EP2561368B1/en active Active
-
2016
- 2016-12-16 JP JP2016243869A patent/JP6580546B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-22 HK HK19101066.6A patent/HK1258688A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6580546B2 (ja) | 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 | |
| Foong et al. | The effects of in utero vitamin D deficiency on airway smooth muscle mass and lung function | |
| JP6782698B2 (ja) | がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法 | |
| Fernandez-Gallardo et al. | Adenosine stimulate proliferation and migration in triple negative breast cancer cells | |
| Rullman et al. | Circulatory factors associated with function and prognosis in patients with severe heart failure | |
| Schurman et al. | Age-related disease association of endogenous γ-H2AX foci in mononuclear cells derived from leukapheresis | |
| Tran et al. | Micro-RNAs are related to epicardial adipose tissue in participants with atrial fibrillation: data from the MiRhythm study | |
| TWI567391B (zh) | 辨識早期肺腺癌病患之次群組之生物標記 | |
| TW202409065A (zh) | 使用ａｔｒ／ｃｈｋ１傳訊途徑抑制劑治療疾病之方法及系統 | |
| CN106290653B (zh) | 与特发性男性不育相关的尿液脂肪酸代谢物标志物及其检测方法和应用 | |
| Totoń-Żurańska et al. | MicroRNA composition of plasma extracellular vesicles: a harbinger of late cardiotoxicity of doxorubicin | |
| JP2022091828A (ja) | 併用抗がん剤の感受性の判定マーカー | |
| Shah et al. | Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma | |
| Liang et al. | Raman spectroscopy and bioinformatics-based identification of key genes and pathways capable of distinguishing between diffuse large B cell lymphoma and chronic lymphocytic leukemia | |
| JP5758690B2 (ja) | 併用化学療法の奏効性判定方法、奏効性判定プログラム及び奏効性判定装置 | |
| CN119574871B (zh) | 一种用于预测胆管癌免疫治疗预后的分子标志物bst2及其应用 | |
| RU2710264C1 (ru) | Способ прогнозирования развития липидного дистресс-синдрома у пациентов с устойчивым вирусологическим ответом на противовирусную терапию хронического гепатита с | |
| Gupta et al. | Clinical assessment of cardiovascular disorders by cardiac biomarkers | |
| CN116622846A (zh) | 用于弥漫大B细胞淋巴瘤诊断的外周血circRNA生物标志物及其应用 | |
| Simic-Ogrizovic et al. | Risk factors associated with coronary artery calcification should be examined before kidney transplantation | |
| CN116676387A (zh) | 一种用于胃癌诊断的标志物及其应用 | |
| Pawlak et al. | Frequency of viral nucleic acids detection using real-time PCR in endomyocardial biopsy samples, blood samples from the ventricle and peripheral blood in patients with dilated cardiomyopathy | |
| Haini et al. | 13P Expression of Notch 1 and Notch 3 proteins in imprints of NSCLC: Correlation with prognostic factors | |
| Berry et al. | New heart failure diagnostic and prognostic biomarkers discovered using capillary electrophoresis coupled to mass spectroscopy |